| Autor: |
Martelle SE; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA.; Wake Forest Innovations, Wake Forest University Health Sciences, Winston-Salem, NC, USA., Cotella EM; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA.; Cincinnati Veterans Administration Medical Center, Cincinnati, OH, USA., Nawreen N; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA.; Neuroscience Graduate Program, University of Cincinnati, Cincinnati, OH, USA., Chen C; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA., Packard BA; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA., Fitzgerald M; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA., Herman JP; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA.; Cincinnati Veterans Administration Medical Center, Cincinnati, OH, USA.; Neuroscience Graduate Program, University of Cincinnati, Cincinnati, OH, USA. |
| Abstrakt: |
Pituitary adenylate cyclase-activating polypeptide (PACAP) is an excitatory neuromodulatory peptide strongly implicated in nervous stress processing. Human polymorphism of the primary PACAP receptor (PAC1) is linked to psychiatric disorders, including posttraumatic stress disorder (PTSD). Prefrontal cortex PACAP signaling is associated with processing of traumatic stress and fear learning, suggesting a potential role in PTSD-related deficits. We used RNAscope to define the cellular location of PACAP and PAC1 in the infralimbic cortex (IL). Subsequent experiments used a pharmacological approach to assess the impact of IL PACAP infusion on behavioral and physiological stress response and fear memory. Adult male Sprague-Dawley rats were bilaterally microinjected with PACAP (1 ug) or vehicle into the IL, 30 minutes prior to forced swim test (FST). Blood was sampled at 15, 30, 60, and 120 minutes for analysis of hypothalamic pituitary adrenal (HPA) axis reactivity. Five days after, animals were tested in a 3-day passive avoidance paradigm with subsequent testing of fear retention two weeks later. We observed that PACAP is highly expressed in putative pyramidal neurons (identified by VGlut1 expression), while PAC1 is enriched in interneurons (identified by GAD). Pretreatment with PACAP increased active coping style in the FST, despite higher levels of ACTH and corticosterone. The treatment was also sufficient to cause an increase in anxiety-like behavior in a dark/light crossover test and enhanced retention of passive avoidance. Our data suggest that IL PACAP plays a role in driving stress responses and in processing of fear memories, likely mediated by inhibition of cortical drive. |
